This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Rain Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0. Rain Oncology's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2024-05-17), Rain Oncology's share price is $1.21. Rain Oncology's Median PS Value is $0.00. Therefore, Rain Oncology's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Rain Oncology's Median PS Value or its related term are showing as below:
RAIN's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.71 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Rain Oncology Median PS Value Historical Data
The historical data trend for Rain Oncology's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rain Oncology's Median PS Value
For the Biotechnology subindustry, Rain Oncology's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rain Oncology's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rain Oncology's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Rain Oncology's Price-to-Median-PS-Value falls into.
Rain Oncology Median PS Value Calculation
Rain Oncology's Median PS Value for today is calculated as
10-Year Median PS Ratio is .
Rain Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rain Oncology (NAS:RAIN) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Rain Oncology's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.21
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rain Oncology Median PS Value Related Terms
Thank you for viewing the detailed overview of Rain Oncology's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Rain Oncology (Rain Oncology) Business Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RAIN has been successfully added to your 